Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Harvoni U.S. Sales Dip Reflects Progress In Treating Sickest Patients, Gilead Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Overall HCV sales continue to grow at Gilead despite some softness in the U.S. market – one near-term positive is Sovaldi should launch in the U.K. soon, followed quickly by Harvoni.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register